Abstract

Urinary tract infections (UTIs) pose a threat especially to women, the individuals with weakened immunity or with abnormalities in the urinary tract as well as to hospitalized and catheterized patients. The bacteria from the genus Proteus, especially P. mirabilis, are important UTI pathogenic factors. They frequently cause chronic, recurrent or severely complicated infections, resulting in the urinary stones production due to urease and other virulence factors. The ability to survive inside the stones and the increasing antibiotic resistance make it difficult to eradicate the bacteria from the urinary tract. A good solution to the problem may be the vaccination which obtained the interest from the surveyed persons, in spite of the antivaccination attitudes visible also in Poland. Currently, there are four vaccines available, composed of killed cells of different uropathogens, including Proteus spp. They are administrated intranassaly or vaginally and require many booster doses. They decrease the probability of reinfection in patients suffering from recurrent UTIs but the mechanisms of the immune response have not been exactly defined. Promising results were obtained in the studies on a mice model concerning the subunit, conjugated vaccines in which various P. mirabilis surface antigens (with the exception of flagellin) were successfully employed. Hitherto, the best results were obtained by the intranasal vaccinations, using MR/P fimbriae antigens with MPL or cholera toxin adjuvants and the antigens expressed in Lactococcus lactis or Salmonella Typhimurium. It led to an increase in the levels of the specific serum and mucosal antibodies resulting in the protection against P. mirabilis UTIs.

References

• 1. Alamuri P., Eaton K.A., Himpsl S.D., Smith S.N., Mobley H.L.: Vaccinationwith proteus toxic agglutinin, a hemolysin-independentcytotoxin in vivo, protects against Proteus mirabilis urinary tractinfection. Infect. Immun., 2009; 77: 632-641
  Google Scholar
• 2. Arbatsky N.P., Drzewiecka D., Palusiak A., Shashkov A.S., ZabłotniA., Siwińska M., Knirel Y.A.: Structure of a Kdo-containing O polysacchariderepresenting Proteus O79, a newly described serogroupfor some clinical Proteus genomospecies isolates from Poland. Carbohydr.Res., 2013; 379: 100-105
  Google Scholar
• 3. Armbruster C.E., Mobley H.L.: Merging mythology and morphology:the multifaceted lifestyle of Proteus mirabilis. Nat. Rev. Microbiol.,2012; 10: 743-754
  Google Scholar
• 4. Bahrani F.K., Johnson D.E., Robbins D., Mobley H.L.: Proteus mirabilisflagella and MR/P fimbriae: isolation, purification, N-terminalanalysis, and serum antibody response following experimental urinarytract infection. Infect. Immun., 1991; 59: 3574-3580
  Google Scholar
• 5. Bochniewska V., Jung A., Żuber J.: Zakażenie układu moczowegou dzieci. Pediatr. Med. Rodz., 2012; 8, 12-22
  Google Scholar
• 6. Brumbaugh A.R., Mobley H.L.: Preventing urinary tract infection:progress toward an effective Escherichia coli vaccine. Expert.Rev. Vaccines, 2012; 11: 663-676
  Google Scholar
• 7. Burne R.A., Chen Y.Y.: Bacterial ureases in infectious diseases.Microbes Infect., 2000; 2: 533-542
  Google Scholar
• 8. Carraro-Eduardo J.C., Gava I.A.: Use of vaccines for prophylaxis ofurinary tract infections. J. Bras. Nefrol., 2012; 34: 178-183
  Google Scholar
• 9. Coban B., Ülkü N., Kaplan H., Topal B., Erdogan H., Baskin E.: Fiveyearassessment of causative agents and antibiotic resistances inurinary tract infections. Turk Pediatri Ars., 2014; 49: 124-129
  Google Scholar
• 10. Cohen-Nahum K., Saidel-Odes L., Riesenberg K., Schlaeffer F.,Borer A.: Urinary tract infections caused by multi-drug resistantProteus mirabilis: risk factors and clinical outcomes. Infection, 2010;38: 41-46
  Google Scholar
• 11. Coker C., Poore C.A., Li X., Mobley H.L.: Pathogenesis of Proteusmirabilis urinary tract infection. Microbes Infect., 2000; 2: 1497-1505
  Google Scholar
• 12. Cuevas O., Cercenado E., Gimeno M., Marín M., Coronel P., BouzaE.: Comparative in vitro activity of cefditoren and other antimicrobialsagainst Enterobacteriaceae causing community-acquired uncomplicatedurinary tract infections in women: a Spanish nationwidemulticenter study. Diagn. Microbiol. Infect. Dis., 2010; 67: 251-260
  Google Scholar
• 13. Czekalski S.: Zakażenie układu moczowego – ostre, nawracające,przewlekłe, powikłane. Przewodnik Lekarza, 2010; 2: 46-53
  Google Scholar
• 14. Drzewiecka D., Arbatsky N.P., Shashkov A.S., Stączek P., KnirelY.A., Sidorczyk Z.: Structure and serological properties of the O-antigenof two clinical Proteus mirabilis strains classified into a new ProteusO77 serogroup. FEMS Immunol. Med. Microbiol., 2008; 54: 185-194
  Google Scholar
• 15. Drzewiecka D., Arbatsky N.P., Stączek P., Shashkov A.S., KnirelY.A., Sidorczyk Z.: Structural and serological studies of the O-polysaccharideof strains from a newly created Proteus O78 serogroupPiśmiennictwoprevalent in Polish patients. FEMS Immunol. Med. Microbiol., 2010;58: 269-276
  Google Scholar
• 16. Habibi M., Asadi Karam M.R., Bouzari S.: Evaluation of the effectof MPL and delivery route on immunogenicity and protectivityof different formulations of FimH and MrpH from uropathogenicEscherichia coli and Proteus mirabilis in a UTI mouse model. Int. Immunopharmacol.,2015; 28: 70-78
  Google Scholar
• 17. Habibi M., Asadi Karam M.R., Shokrgozar M.A., Oloomi M.,Jafari A., Bouzari S.: Intranasal immunization with fusion proteinMrpH·FimH and MPL adjuvant confers protection against urinarytract infections caused by uropathogenic Escherichia coli and Proteusmirabilis. Mol. Immunol., 2015; 64: 285-294
  Google Scholar
• 18. Hola V., Peroutkova T., Ruzicka F.: Virulence factors in Proteusbacteria from biofilm communities of catheter-associated urinarytract infections. FEMS Immunol. Med. Microbiol., 2012; 65: 343-349
  Google Scholar
• 19. Hopkins W.J., Elkahwaji J., Beierle L.M., Leverson G.E., UehlingD.T.: Vaginal mucosal vaccine for recurrent urinary tract infectionsin women: results of a phase 2 clinical trial. J. Urol., 2007; 177: 1349-1353
  Google Scholar
• 20. Hopkins W.J., Uehling D.T.: Vaccine development for the preventionof urinary tract infections. Curr. Infect. Dis. Rep., 2002; 4: 509-513
  Google Scholar
• 21. Jacobsen S.M., Shirtliff M.E.: Proteus mirabilis biofilms and catheter-associatedurinary tract infections. Virulence, 2011; 2: 460-465
  Google Scholar
• 22. Jarząb A., Skowicki M., Witkowska D.: Szczepionki podjednostkowe– antygeny, nośniki, metody koniugacji i rola adiuwantów.Postępy Hig. Med. Dośw., 2013; 67: 1128-1143
  Google Scholar
• 23. Johnson D.E., Bahrani F.K., Lockatell C.V., Drachenberg C.B.,Hebel J.R., Belas R., Warren J.W., Mobley H.L.: Serum immunoglobulinresponse and protection from homologous challenge by Proteusmirabilis in a mouse model of ascending urinary tract infection. Infect.Immun., 1999; 67: 6683-6687
  Google Scholar
• 24. Jones R.J.: Oral vaccination against Proteus mirabilis. Br. J. Exp.Pathol., 1976; 57: 395-399
  Google Scholar
• 25. Khan A.U., Musharraf A.: Plasmid-mediated multiple antibioticresistance in Proteus mirabilis isolated from patients with urinarytract infection. Med. Sci. Monit., 2004; 10: 598-602
  Google Scholar
• 26. Kiliś-Pstrusińska K.: Zakażenia układu moczowego. PraktykaLekarska, 2012; 72: 5-13
  Google Scholar
• 27. Knirel Y.A., Perepelov A.V., Kondakova A.N., Senchenkova S.N.,Sidorczyk Z., Różalski A., Kaca W.: Structure and serology of O-antigensas the basis for classification of Proteus strains. Innate Immun.,2011; 17: 70-96
  Google Scholar
• 28. Kwil I., Kaźmierczak D., Różalski A.: Swarming growth and resistanceof Proteus penneri and Proteus vulgaris strains to normal humanserum. Adv. Clin. Exp. Med., 2013; 22: 165-175
  Google Scholar
• 29. Li X., Erbe J.L., Lockatell C.V., Johnson D.E., Jobling M.G., HolmesR.K., Mobley H.L.: Use of translational fusion of the MrpH fimbrialadhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccineto prevent experimental urinary tract infection by Proteus mirabilis.Infect. Immun., 2004; 72: 7306-7310
  Google Scholar
• 30. Li X., Lockatell C.V., Johnson D.E., Lane M.C., Warren J., MobleyH. L.: Development of an intranasal vaccine to prevent urinarytract infection by Proteus mirabilis. Infect. Immun., 2004; 72: 66-75
  Google Scholar
• 31. Li X., Mobley H.L.: Vaccines for Proteus mirabilis in urinary tractinfection. Int. J. Antimicrob. Agents, 2002; 19: 461-465
  Google Scholar
• 32. Lorenzo-Gómez M.F., Padilla-Fernández B., García-Criado F.J.,Mirón-Canelo J.A., Gil-Vicente A., Nieto-Huertos A., Silva-Abuin J.M.:Evaluation of a therapeutic vaccine for the prevention of recurrenturinary tract infections versus prophylactic treatment with antibiotics.Int. Urogynecol. J., 2013; 24: 127-134
  Google Scholar
• 33. Lorenzo-Gómez M.F., Padilla-Fernández B., García-CenadorM.B., Virseda-Rodríguez Á.J., Martín-García I., Sánchez-EscuderoA., Vicente-Arroyo M.J., Mirón-Canelo J.A.: Comparison of sublingualtherapeutic vaccine with antibiotics for the prophylaxis ofrecurrent urinary tract infections. Front. Cell. Infect. Microbiol.,2015; 5: 50
  Google Scholar
• 34. Maraki S., Mantadakis E., Michailidis L., Samonis G.: Changingantibiotic susceptibilities of community-acquired uropathogens inGreece, 2005-2010. J. Microbiol. Immunol. Infect., 2013; 46: 202-209
  Google Scholar
• 35. Marchewka A.K., Majewska A., Młynarczyk G.: Działalność ruchuantyszczepionkowego, rola środków masowego komunikowania orazwpływ poglądów religijnych na postawę wobec szczepień ochronnych.Post. Mikrobiol., 2015; 54: 95-102
  Google Scholar
• 36. Moayeri N., Collins C.M., O’Hanley P.: Efficacy of a Proteus mirabilisouter membrane protein vaccine in preventing experimentalProteus pyelonephritis in a BALB/c mouse model. Infect. Immun.,1991; 59: 3778-3786
  Google Scholar
• 37. Moryl M., Torzewska A., Jałmużna P., Różalski A.: Analysis ofProteus mirabilis distribution in multi-species biofilms on urinarycatheters and determination of bacteria resistance to antimicrobialagents. Pol. J. Microbiol., 2013; 62: 377-384
  Google Scholar
• 38. Nicolle L.E.: Resistant pathogens in urinary tract infections. J.Am. Geriatr. Soc., 2002; 50: S230-S235
  Google Scholar
• 39. Nielubowicz G.R., Smith S.N., Mobley H.L.: Outer membraneantigens of the uropathogen Proteus mirabilis recognized by the humoralresponse during experimental murine urinary tract infection.Infect. Immun., 2008; 76: 4222-4231
  Google Scholar
• 40. O’Hara C.M., Brenner F.W., Steigerwalt A.G., Hill B.C., Holmes B.,Grimont P.A., Hawkey P.M., Penner J.L., Miller J.M., Brenner D.: Classificationof Proteus vulgaris biogroup 3 with recognition of Proteushauseri sp. nov., nom. rev. and unnamed Proteus genomospecies 4, 5and 6. Int. J. Syst. Evol. Microbiol., 2000; 50: 1869-1875
  Google Scholar
• 41. Okrągła E., Szychowska K., Wolska L.: Mechanizmy utrzymaniasterylności układu moczowego. Postępy Hig. Med. Dośw., 2014;68: 684-694
  Google Scholar
• 42. Ostrowska K., Strzelczyk A., Różalski A., Stączek P.: Biofilm bakteryjnyjako przyczyna zakażeń układu moczowego – mikroorganizmypatogenne, metody prewencji i eradykacji. Postępy Hig. Med.Dośw., 2013; 67: 1027-1033
  Google Scholar
• 43. Pellegrino R., Galvalisi U., Scavone P., Sosa V., Zunino P.: Evaluationof Proteus mirabilis structural fimbrial proteins as antigensagainst urinary tract infections. FEMS Immunol. Med. Microbiol.,2003; 36: 103-110
  Google Scholar
• 44. Ronald A.: The etiology of urinary tract infection: traditionaland emerging pathogens. Am. J. Med., 2002; 113: 14S-19S
  Google Scholar
• 45. Różalski A., Torzewska A., Moryl M., Kwil I., Maszewska A., OstrowskaK., Drzewiecka D., Zabłotni A., Palusiak A., Siwińska M.,Stączek P.: Proteus sp. – an opportunistic bacterial pathogen – classification,swarming growth, clinical significance and virulence factors.Folia Biol. Oecol., 2012; 8: 1-17
  Google Scholar
• 46. Scavone P., Miyoshi A., Rial A., Chabalgoity A., Langella P., AzevedoV., Zunino P.: Intranasal immunisation with recombinant Lactococcuslactis displaying either anchored or secreted forms of Proteusmirabilis MrpA fimbrial protein confers specific immune responseand induces a significant reduction of kidney bacterial colonisationin mice. Microbes Infect., 2007; 9: 821-828
  Google Scholar
• 47. Scavone P., Rial A., Umpierrez A., Chabalgoity A., Zunino P.: Effectsof the administration of cholera toxin as a mucosal adjuvanton the immune and protective response induced by Proteus mirabilisMrpA fimbrial protein in the urinary tract. Microbiol. Immunol.,2009; 53: 233-240
  Google Scholar
• 48. Scavone P., Sosa V., Pellegrino R., Galvalisi U., Zunino P.: Mucosalvaccination of mice with recombinant Proteus mirabilis structuralfimbrial proteins. Microbes Infect., 2004; 6: 853-860
  Google Scholar
• 49. Scavone P., Umpiérrez A., Maskell D.J., Zunino P.: Nasal immunizationwith attenuated Salmonella Typhimurium expressing anMrpA-TetC fusion protein significantly reduces Proteus mirabiliscolonization in the mouse urinary tract. J. Med. Microbiol., 2011;60: 899–904
  Google Scholar
• 50. Scavone P., Umpiérrez A., Rial A., Chabalgoity J.A., Zunino P.:Native flagellin does not protect mice against an experimental Proteusmirabilis ascending urinary tract infection and neutralizes theprotective effect of MrpA fimbrial protein. Antonie van Leeuwenhoek,2014; 105: 1139-1148
  Google Scholar
• 51. Siwińska M., Levina E.A., Ovchinnikova O.G., Drzewiecka D.,Shashkov A.S., Różalski A., Knirel Y.A.: Classification of a Proteuspenneri clinical isolate with a unique O-antigen structure to a newProteus serogroup, O80. Carbohydr. Res., 2015; 407: 131-136
  Google Scholar
• 52. Sosa V., Schlapp G., Zunino P.: Proteus mirabilis isolates of differentorigins do not show correlation with virulence attributes and cancolonize the urinary tract of mice. Microbiology, 2006; 152: 2149-2157
  Google Scholar
• 53. Stamm W.E.: Scientific and clinical challenges in the managementof urinary tract infections. Am. J. Med., 2002; 113: 1S-4S
  Google Scholar
• 54. Stickler D., Hughes G.: Ability of Proteus mirabilis to swarm overurethral catheters. Eur. J. Clin. Microbiol. Infect. Dis., 1999; 18: 206-208
  Google Scholar
• 55. Tajbakhsh E., Tajbakhsh S., Khamesipour F.: Isolation and moleculardetection of Gram-negative bacteria causing urinary tractinfection in patients referred to Shahrekord hospitals, Iran. Iran.Red Crescent Med. J., 2015; 17: e24779
  Google Scholar
• 56. Torzewska A.: Udział drobnoustrojów w powstawaniu kamienimoczowych. Postępy Mikrobiol., 2003; 42: 39-53
  Google Scholar
• 57. Umpiérrez A., Scavone P., Romanin D., Marqués J.M., ChabalgoityJ.A., Rumbo M., Zunino P.: Innate immune responses to Proteus mirabilisflagellin in the urinary tract. Microbes Infect., 2013; 15: 688-696
  Google Scholar
• 58. Wang M.C., Chien H.F., Tsai Y.L., Liu M.C., Liaw S.J.: The RNAchaperone Hfq is involved in stress tolerance and virulence in uropathogenicProteus mirabilis. PLoS One, 2014; 9: e85626
  Google Scholar
• 59. Wyszyńska A., Kobierecka P., Jagusztyn-Krynicka E.K.: Bakteriekwasu mlekowego (LAB) jako wektory do konstrukcji szczepionek.Postępy Mikrobiol., 2015; 54: 141-153
  Google Scholar
• 60. Zhang Y., Yang S., Dai X., Liu L., Jiang X., Shao M., Chi S., WangC., Yu C., Wei K., Zhu R.: Protective immunity induced by the vaccinationof recombinant Proteus mirabilis OmpA expressed in Pichiapastoris. Protein Expr. Purif., 2015; 105: 33-38
  Google Scholar

Full text